An investigational new agent called tasquinimod may help increase survival in men with metastatic prostate cancer

This oral agent has been found to extend progression-free survival by a mean of 7.6 months compared with 3.3 months for placebo.


Continue Reading

John Schieszer has the latest on this new agent in today’s Medical Minute.